Kopran Ltd (KOPRAN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 568367, "name": "Kopran", "stock_name": "Kopran", "full_name": "Kopran Ltd", "name_url": "stocks-analysis/kopran", "exchange": 1, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "133.91", "chg": 10.67, "chgp": "8.66%", "dir": 1, "prev_price": "123.24", "mcapval": "623.00 Cr", "mcap": "Micro Cap", "scripcode": 524280, "symbol": "KOPRAN", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE082A01010", "curr_date": "Feb 03", "curr_time": "", "bse_nse_vol": "5.35 lacs", "exc_status": "Active", "traded_date": "Feb 03, 2026", "traded_date_str": "2026 02 03", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kopran-568367-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Kopran Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/kopran-ltd-is-rated-strong-sell-3816027", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/KopranLtd_mojoScore_3816027.png", "date": "2026-02-02 10:11:05", "description": "Kopran Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with the most up-to-date view of the company’s performance and outlook." }, { "title": "Kopran Ltd Stock Falls to 52-Week Low of Rs.123.2 Amid Continued Underperformance", "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-stock-falls-to-52-week-low-of-rs1232-amid-continued-underperformance-3815968", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/KopranLtd_priceRelatedfactors_3815968.png", "date": "2026-02-02 09:48:37", "description": "Kopran Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.123.2 today, marking a significant milestone in its ongoing price decline. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance and market positioning." }, { "title": "Kopran Ltd Falls 9.79%: 4 Key Factors Driving the Weekly Decline", "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-falls-979-4-key-factors-driving-the-weekly-decline-3803615", "imagepath": "", "date": "2026-01-24 17:00:08", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Jan 19:</strong> Stock opens at ₹142.55, down 1.72% amid weak market sentiment</p>\n <p><strong>Jan 20:</strong> Downgrade to Strong Sell announced, stock falls 4.67% to ₹135.90</p>\n <p><strong>Jan 21:</strong> Bearish technical signals intensify, stock closes near ₹135.60</p>\n <p><strong>Jan 22:</strong> Mixed quarterly results released, slight uptick to ₹135.75</p>\n <p><strong>Jan 23:</strong> Financial trend improves marginally, but stock closes lower at ₹130.85</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open..." }, { "title": "Are Kopran Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-kopran-ltd-latest-results-good-or-bad-3802450", "imagepath": "", "date": "2026-01-23 19:16:34", "description": "Kopran Ltd's latest financial results for Q3 FY26 present a complex picture of growth and challenges. The company reported a net profit of ₹9.34 crores, which reflects a decline of 10.19% year-on-year, despite a recovery from a loss in the previous quarter. Revenue for the same period was ₹194.28 crores, showcasing a significant quarter-on-quarter growth of 64.77% and a year-on-year increase of 16.87%. This revenue growth, however, is accompanied by concerns regarding profitability, as the operating margin (excluding other income) decreased to 9.15%, down from 11.93% a year prior, indicating rising operational costs that have outpaced revenue growth.\n\nThe profit after tax (PAT) margin also contracted to 4.81%, down from 6.26% in the corresponding quarter last year, highlighting ongoing challenges in maintaining bottom-line efficiency. Additionally, the company's return on equity (ROE) and return on capital ..." }, { "title": "Kopran Ltd Reports Mixed Quarterly Results Amid Financial Trend Improvement", "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-reports-mixed-quarterly-results-amid-financial-trend-improvement-3800923", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/KopranLtd_fintrenddot_3800923.png", "date": "2026-01-23 08:00:10", "description": "Kopran Ltd’s latest quarterly results for December 2025 reveal a modest improvement in its financial trend, shifting from very negative to negative territory. Despite achieving record net sales and improved cash reserves, the pharmaceutical company continues to grapple with declining profitability and rising interest costs, underscoring persistent operational challenges in a competitive sector." }, { "title": "Kopran Ltd Q3 FY26: Margin Squeeze Amid Revenue Volatility Raises Profitability Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/kopran-ltd-q3-fy26-margin-squeeze-amid-revenue-volatility-raises-profitability-concerns-3800669", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/Kopran_quaterlyResult_3800669.png", "date": "2026-01-22 18:30:51", "description": "Kopran Limited, a Mumbai-based pharmaceutical manufacturer specialising in penicillin and non-penicillin-based drugs, reported net profit of ₹9.34 crores for Q3 FY26 (October-December 2025), marking a sharp reversal from the previous quarter's loss but representing a 10.19% year-on-year decline. The company's shares, trading at ₹135.75 on the National Stock Exchange, have witnessed a significant correction of 33.78% over the past year, substantially underperforming both the benchmark Sensex and the broader pharmaceuticals sector." }, { "title": "Kopran Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals", "link": "https://www.marketsmojo.com/news/stock-recommendation/kopran-ltd-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-3797825", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/KopranLtd_mojoScore_3797825.png", "date": "2026-01-21 08:15:01", "description": "Kopran Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 20 Jan 2026. This shift reflects deteriorating technical indicators, disappointing financial trends, and concerns over valuation and quality metrics, signalling heightened caution for investors amid ongoing underperformance." }, { "title": "Kopran Ltd Faces Intensified Downward Momentum Amid Bearish Technical Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-faces-intensified-downward-momentum-amid-bearish-technical-signals-3797633", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/KopranLtd_technicaldot_3797633.png", "date": "2026-01-21 08:02:10", "description": "Kopran Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a bearish trend. Despite some bullish cues on the weekly On-Balance Volume (OBV), the overall technical landscape points to increased selling pressure, reflected in a 3.23% drop in the stock price to ₹137.95 on 21 Jan 2026. This article analyses the evolving technical parameters, compares Kopran’s performance against the Sensex, and assesses the implications for investors." }, { "title": "When is the next results date for Kopran Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-kopran-ltd-3792326", "imagepath": "", "date": "2026-01-14 23:15:44", "description": "The next results date for Kopran Ltd is scheduled for January 22, 2026...." } ], "total": 270, "sid": "568367", "stock_news_url": "https://www.marketsmojo.com/news/kopran-568367" }, "announcements": [ { "details": "Kopran Limited has informed the Exchange regarding Disclosure of Related Party Transactions pursuant to Regulation 23(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended September 30, 2019", "source": "NSE", "caption": "Kopran Limited - Other General Purpose", "datetime": "08-Nov-2019" }, { "details": " <table><tr><td>Kopran Limited has informed the Exchange regarding Board meeting held on September 11, 2019. </td></tr></table>", "source": "NSE", "caption": "Outcome of Board Meeting", "datetime": "11-Sep-2019" }, { "details": " <table><tr><td>Kopran Limited has submitted to the Exchange, the financial results for the period ended June 30, 2019. </td></tr></table>", "source": "NSE", "caption": "Financial Result Updates", "datetime": "08-Aug-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Kopran Ltd has declared <strong>30%</strong> dividend, ex-date: 04 Sep 25", "dt": "2025-09-04", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

Jan 19: Stock opens at ₹142.55, down 1.72% amid weak market sentiment

Jan 20: Downgrade to Strong Sell announced, stock falls 4.67% to ₹135.90

Jan 21: Bearish technical signals intensify, stock closes near ₹135.60

Jan 22: Mixed quarterly results released, slight uptick to ₹135.75

Jan 23: Financial trend improves marginally, but stock closes lower at ₹130.85

Week Open...

Read full news article

Are Kopran Ltd latest results good or bad?

2026-01-23 19:16:34

Kopran Ltd's latest financial results for Q3 FY26 present a complex picture of growth and challenges. The company reported a net profit of ₹9.34 crores, which reflects a decline of 10.19% year-on-year, despite a recovery from a loss in the previous quarter. Revenue for the same period was ₹194.28 crores, showcasing a significant quarter-on-quarter growth of 64.77% and a year-on-year increase of 16.87%. This revenue growth, however, is accompanied by concerns regarding profitability, as the operating margin (excluding other income) decreased to 9.15%, down from 11.93% a year prior, indicating rising operational costs that have outpaced revenue growth. The profit after tax (PAT) margin also contracted to 4.81%, down from 6.26% in the corresponding quarter last year, highlighting ongoing challenges in maintaining bottom-line efficiency. Additionally, the company's return on equity (ROE) and return on capital ...

Read full news article

Kopran Ltd Reports Mixed Quarterly Results Amid Financial Trend Improvement

2026-01-23 08:00:10

Kopran Ltd’s latest quarterly results for December 2025 reveal a modest improvement in its financial trend, shifting from very negative to negative territory. Despite achieving record net sales and improved cash reserves, the pharmaceutical company continues to grapple with declining profitability and rising interest costs, underscoring persistent operational challenges in a competitive sector.

Read full news article

Kopran Ltd Q3 FY26: Margin Squeeze Amid Revenue Volatility Raises Profitability Concerns

2026-01-22 18:30:51

Kopran Limited, a Mumbai-based pharmaceutical manufacturer specialising in penicillin and non-penicillin-based drugs, reported net profit of ₹9.34 crores for Q3 FY26 (October-December 2025), marking a sharp reversal from the previous quarter's loss but representing a 10.19% year-on-year decline. The company's shares, trading at ₹135.75 on the National Stock Exchange, have witnessed a significant correction of 33.78% over the past year, substantially underperforming both the benchmark Sensex and the broader pharmaceuticals sector.

Read full news article

Kopran Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

2026-01-21 08:15:01

Kopran Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 20 Jan 2026. This shift reflects deteriorating technical indicators, disappointing financial trends, and concerns over valuation and quality metrics, signalling heightened caution for investors amid ongoing underperformance.

Read full news article

Kopran Ltd Faces Intensified Downward Momentum Amid Bearish Technical Signals

2026-01-21 08:02:10

Kopran Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a bearish trend. Despite some bullish cues on the weekly On-Balance Volume (OBV), the overall technical landscape points to increased selling pressure, reflected in a 3.23% drop in the stock price to ₹137.95 on 21 Jan 2026. This article analyses the evolving technical parameters, compares Kopran’s performance against the Sensex, and assesses the implications for investors.

Read full news article

When is the next results date for Kopran Ltd?

2026-01-14 23:15:44

The next results date for Kopran Ltd is scheduled for January 22, 2026....

Read full news article